<DOC>
	<DOCNO>NCT01102387</DOCNO>
	<brief_summary>The aim study determine efficacy safety daily topical application combinational cream LAS41003 compare correspond mono-substances treatment candida infection intertriginous area trunk .</brief_summary>
	<brief_title>Efficacy Safety LAS41003 Treatment Intertriginous Candida Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<criteria>presence candida infection one intertriginous area ( trunk ) , confirm positive mycological sample baseline ; female volunteer childbearing potential must either surgically sterile ( hysterectomy tubal ligation ) agree use reliable method contraception failure rate le 1 % per year use consistently correctly implant , injectables , combine oral contraceptive , intra uterine device [ IUDs ] , sexual abstinence vasectomize partner ; write informed consent receive systemic therapy cytotoxic immunosuppressive drug either concurrently within 12 week baseline visit ; patient treat oral antifungal agent within 12 week prior study entry treat topical antifungal agent intertrigines within previous 2 week ; evidence drug alcohol abuse ; pregnancy nursing ; symptom clinically significant illness may influence outcome study four week study ; treatment investigational drug four week precede study ; know allergic reaction component study preparation , hypersensitivity cetylstearyl alcohol ; treatment systemic locally act medication might counter influence study aim within two week begin study ( e.g . glucocorticosteroids ) ; opinion investigator physician perform initial examination subject participate study , e.g . due probable noncompliance inability</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Candida infection intertriginous area</keyword>
</DOC>